In conclusion, the present findings demonstrated that pretreatment with fingolimod-phosphate enhances the barrier properties of the BBB by upregulating the claudin-5 expression and inhibiting the increased VCAM-1 levels in BMECs induced by MS sera. The gene discussed is VCAM1; the disease is myeloid sarcoma.